**EQUITY RESEARCH - ANALYST MEETING** 

# CHULARAT HOSPITAL

THAILAND / HEALTH CARE SERVICES

**CHG TB** 





# Key takeaways from analyst meeting

#### **TARGET PRICE THB3.60** CLOSE THB2.58 **UP/DOWNSIDE** +39.5% **TP vs CONSENSUS** +9.8%

## **Highlights**

- We attended the analyst meeting and received positive feedback from it.
- Management maintained a revenue growth target of 15%y-y in 2024 (vs 14% in 1H24) and targeted NPM to be at least equal to 2023 (14%). This suggests NPM to improve significantly in 2H24 from 11% in 1H24. Management also saw strong operation in July and Aug.
- Mae Sot revenue increased to 35m in 2Q24 (vs THB25-30m in 1Q24). However, it booked a larger loss of THB28-29m in 2Q24 (vs THB20m in 1Q24) due to higher fixed costs. Therefore, management revised its loss target to THB70-80m in 2024 (vs THB50-60m previously). On a positive note, the loss should narrow in 2H24, given that it has already booked most of the fixed costs.
- CHG expected NHSO to pay the remaining Covid treatments by 3Q24. Note that CHG had cTHB360m account receivable outstanding as of 2Q24 (80% are NHSO's Covid). There is a high potential that CHG will book a gain after clearing it with NHSO as they have advance payments pending realization.
- SSO has made its final payment for 2023 chronic disease treatments. Therefore, CHG would likely book additional revenue since the actual payment exceeded accrued amounts. Note that last year CHG recorded an additional gain of THB87m in 4Q23.
- CHG announced a new project, CHG Rayong International Hospital, in which CHG would hold 70% and a group of partners would hold a 30% stake. This is a 200-bed hospital with a capex of THB1.5b and a schedule to start construction in 4Q24 to open in 2026. Management sees high potential in Rayong province and a strong profile of partners (a group of doctors, nurses, and businessmen in the area).
- CHG is considering extending management contracts with Pattaya City Hospital (ending in Oct-24) and Koh Lan Medical Center (ending in 2025). If they do not extend the contracts, CHG will allocate resources to improve other hospitals in the group. Note that the management service revenue is cTHB300/year with an NPM of less than 10%.
- NHSO has revised down its high-cost-care payment for heart surgery from THB8,350/RW to cTHB7,000/RW for 3Q24. This would have around THB4-8m impact on the 3Q24 profit as NHSO revenue accounted for only 4% of total revenue.

## Recommendation

We maintain our BUY call on CHG. It is trading at a cheap valuation of 24x 2024E P/E. We expect strong organic growth in 3Q24, driven by improving margins during a high healthcare season and a narrower loss from CHG Mae Sot. In addition, CHG would likely book additional gain from SSO chronic disease and NHSO covid treatments in 3Q24.

## **KEY STOCK DATA**

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	7,730	8,462	9,156	9,780
Net profit	1,046	1,203	1,388	1,527
EPS (THB)	0.10	0.11	0.13	0.14
vs Consensus (%)	-	2.8	10.2	5.3
EBITDA	1,822	2,067	2,313	2,518
Recurring net profit	1,046	1,203	1,388	1,527
Core EPS (THB)	0.10	0.11	0.13	0.14
EPS growth (%)	(62.4)	15.0	15.4	10.0
Core P/E (x)	27.1	23.6	20.4	18.6
Dividend yield (%)	2.7	2.5	2.9	3.2
EV/EBITDA (x)	15.4	13.5	11.8	10.6
Price/book (x)	3.8	3.6	3.3	3.0
Net debt/Equity (%)	(8.2)	(11.3)	(17.1)	(22.5)
ROE (%)	13.9	15.5	16.7	17.0



Share price performance	1 Month	3 Month	12 Month		
, ,		•			
Absolute (%)	0.8	(13.4)	(15.1)		
Relative to country (%)	(1.0)	(11.5)	(2.2)		
Mkt cap (USD m)			826		
3m avg. daily turnover (USD m)			1.9		
Free float (%)			43		
Major shareholder	Kannikar Plussind (18%				
12m high/low (THB)	3.40/2.2				
Issued shares (m)			11,000.00		

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities: License no. 080523 teerapol.udo@fssia.com, +66 2646 9969

Exhibit 1: CHG - 2Q24 result summary

	2Q23	3Q23	4Q23	1Q24	2Q24	Ch	ange	2023	2024	Change
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)				
Revenue	1,799	2,093	2,123	2,021	1,985	(2)	10	7,730	8,462	9
Cost of sales (Incl. depreciation)	(1,380)	(1,486)	(1,580)	(1,498)	(1,559)	4	13	(5,723)	(6,196)	8
Gross profit	418	607	543	523	427	(18)	2	2,008	2,266	13
SG&A	(222)	(246)	(243)	(259)	(240)	(7)	8	(911)	(997)	9
Operating profit	196	361	300	264	186	(29)	(5)	1,097	1,269	16
Other operating income	70	77	65	85	70	(18)	1	284	295	4
Interest income	3	1	4	1	(9)	(777)	(374)	9	6	(30)
Equity income	(2)	(5)	(9)	(9)	5	(161)	(313)	(19)	(10)	(48)
EBIT	267	434	361	342	253	(26)	(5)	1,370	1,561	14
Interest expense	(5)	(7)	(9)	(5)	(5)	(3)	3	(24)	(18)	(26)
EBT	262	427	352	337	248	(26)	(5)	1,346	1,543	15
Income tax	(56)	(90)	(73)	(76)	(57)	(25)	2	(279)	(317)	14
Minority interests	(0)	(11)	(5)	3	0			(21)	(22)	5
Core profit	206	326	274	264	192	(27)	(7)	1,046	1,203	15
Extraordinaries										
Net income	206	326	274	264	192	(27)	(7)	1,046	1,203	15
Core EPS (THB)	0.02	0.03	0.02	0.02	0.02	(27)	(7)	0.10	0.11	15
No of share (m)	11,000	11,000	11,000	11,000	11,000	O	0	11,000	11,000	0
Cost (Excl. depreciation)	(1,276)	(1,370)	(1,459)	(1,377)	(1,434)	4	12	(5,282)	(5,693)	8
Depreciation & amortisation	(104)	(117)	(121)	(121)	(124)	3	19	(441)	(503)	14
EBITDA	370	554	486	470	381	(19)	3	1,822	2,067	13
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)
Gross margin	23	29	26	26	22	(4)	(2)	26	27	1
SG&A/Revenue	12	12	11	13	12	(1)	(0)	12	12	0
EBITDA margin	21	26	23	23	19	(4)	(1)	24	24	1
Net profit margin	11	16	13	13	10	(3)	(2)	14	14	1
Operating stats	(y-y %)									
SSO revenue	23	8	11	11	(2)					
SSO registered members ('000)	528	529	530	537						
SSO revenue per head	17	5	8	9						
Cash-OPD revenue	(20)	(6)	24	19	15					
Cash-OPD visit number	(7)	2	11	10						
Cash-OPD revenue per head	(13)	(8)	12	8						
•	5	24	22	19	12					
Cash-IPD revenue										
Cash-IPD revenue  Cash-IPD admission number	30	29	29	10						

Sources: CHG; FSSIA estimates

## **Financial Statements**

Chularat Hospital

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	10,103	7,730	8,462	9,156	9,780
Cost of goods sold	(5,908)	(5,723)	(6,196)	(6,623)	(7,024)
Gross profit	4,195	2,008	2,266	2,533	2,756
Other operating income	305	284	295	304	313
Operating costs	(935)	(911)	(997)	(1,060)	(1,123)
Operating EBITDA	3,947	1,822	2,067	2,313	2,518
Depreciation	(382)	(441)	(503)	(536)	(571)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	3,565	1,381	1,565	1,777	1,946
Net financing costs	(10)	(15)	(12)	2	5
Associates	(1)	(19)	(10)	(4)	1
Recurring non-operating income	(1)	(19)	(10)	(4)	1
Non-recurring items	0	0	0	0	0
Profit before tax	3,554	1,346	1,543	1,776	1,952
Tax	(703)	(279)	(317)	(364)	(399)
Profit after tax	2,850	1,067	1,225	1,412	1,554
Minority interests	(72)	(21)	(22)	(24)	(26)
Preferred dividends	· · ·	• •	• •	• •	-
Other items	-	-	-	-	-
Reported net profit	2,778	1,046	1,203	1,388	1,527
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	2,778	1,046	1,203	1,388	1,527
Per share (THB)					
Recurring EPS *	0.25	0.10	0.11	0.13	0.14
Reported EPS	0.25	0.10	0.11	0.13	0.14
DPS	0.16	0.07	0.07	80.0	0.08
Diluted shares (used to calculate per share data)	11,000	11,000	11,000	11,000	11,000
Growth					
Revenue (%)	(14.0)	(23.5)	9.5	8.2	6.8
Operating EBITDA (%)	(30.1)	(53.8)	13.5	11.9	8.8
Operating EBIT (%)	(32.7)	(61.3)	13.3	13.6	9.5
Recurring EPS (%)	(33.9)	(62.4)	15.0	15.4	10.0
Reported EPS (%)	(33.9)	(62.4)	15.0	15.4	10.0
Operating performance					
Gross margin inc. depreciation (%)	41.5	26.0	26.8	27.7	28.2
Gross margin exc. depreciation (%)	45.3	31.7	32.7	33.5	34.0
Operating EBITDA margin (%)	39.1	23.6	24.4	25.3	25.7
Operating EBIT margin (%)	35.3	17.9	18.5	19.4	19.9
Net margin (%)	27.5	13.5	14.2	15.2	15.6
Effective tax rate (%)	19.8	20.4	20.4	20.4	20.4
Dividend payout on recurring profit (%)	63.3	73.6	60.0	60.0	60.0
Interest cover (X)	349.5	88.7	132.8	(784.4)	(399.2)
Inventory days	18.5	20.8	22.4	22.5	22.6
Debtor days	24.8	38.5	39.5	38.2	35.8
Creditor days	55.9	60.3	59.5	59.8	60.0
Operating ROIC (%)	47.1	15.9	17.1	19.1	20.8
ROIC (%)	45.1	14.9	16.3	18.3	20.0
ROE (%)	36.8	13.9	15.5	16.7	17.0
ROA (%)	27.4	10.5	12.1	13.4	13.7
* Pre exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Cash patient revenue	5,160	5,025	5,646	6,225	6,733
SSO patient revenue	2,149	2,461	2,560	2,663	2,770

Sources: Chularat Hospital; FSSIA estimates

## **Financial Statements**

Chularat Hospital

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	2,778	1,046	1,203	1,388	1,527
Depreciation	382	441	503	536	571
Associates & minorities	-	-	-	-	
Other non-cash items	117	30	22	24	26
Change in working capital  Cash flow from operations	(696) <b>2,582</b>	435 <b>1,951</b>	(135) <b>1,593</b>	(48) <b>1,900</b>	(42) <b>2,083</b>
Capex - maintenance	(777)	(1,451)	(508)	(549)	(587)
Capex - new investment	(777)	(1,451)	(506)	(349)	(567)
Net acquisitions & disposals	(142)	19	0	0	C
Other investments (net)	(112)	-	-	-	
Cash flow from investing	(919)	(1,432)	(508)	(549)	(587)
Dividends paid	(2,805)	(1,045)	(770)	(722)	(833)
Equity finance	(2,000)	0	0	0	(000)
Debt finance	356	(120)	(705)	0	(
Other financing cash flows	(3)	44	(22)	(24)	(26
Cash flow from financing	(2,452)	(1,121)	(1,497)	(746)	(8 <b>5</b> 9
Non-recurring cash flows	-	-	-	-	
Other adjustments	0	0	0	0	(
Net other adjustments	0	0	0	0	(
Movement in cash	(789)	(601)	(412)	605	637
Free cash flow to firm (FCFF)	1,679.02	543.33	1,103.00	1,353.13	1,498.47
Free cash flow to equity (FCFE)	2,016.07	443.25	357.95	1,326.62	1,470.01
Per share (THB)					
FCFF per share	0.15	0.05	0.10	0.12	0.14
FCFE per share	0.18	0.04	0.03	0.12	0.13
Recurring cash flow per share	0.30	0.14	0.16	0.18	0.19
Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
· · · · · · · · · · · · · · · · · · ·					
Tangible fixed assets (gross)	7,867	9,318	9,825	10,375	10,962
Less: Accumulated depreciation	(2,987)	(3,414)	(3,917)	(4,453)	(5,024)
Tangible fixed assets (net)	4,880	5,903	5,908	5,922	5,937
Intangible fixed assets (net)	47	104	104	104	104
Long-term financial assets Invest. in associates & subsidiaries	142	- 122	- 122	- 122	122
Cash & equivalents	2,001	1,399	987	1,592	2,229
A/C receivable	757	874	959	959	959
Inventories	265	336	363	388	411
Other current assets	2,036	1,436	1,572	1,701	1,817
Current assets	5,058	4,046	3,880	4,639	5,416
Other assets	152	88	88	88	88
Total assets	10,280	10,264	10,104	10,876	11,668
Common equity	7,523	7,525	7,958	8,624	9,31
Minorities etc.	341	406	406	406	406
Total shareholders' equity	7,864	7,931	8,364	9,030	9,72
Long term debt	470	705	0	0	(
Other long-term liabilities	233	247	247	247	24
Long-term liabilities	704	953	247	247	24
A/C payable	851	894	963	1,030	1,09
Short term debt	400	45	45	45	4
Other current liabilities	462	442	484	524	559
Current liabilities	1,712	1,381	1,492	1,599	1,69
Total liabilities and shareholders' equity	10,280	10,264	10,104	10,876	11,66
Net working capital	1,745	1,311	1,446	1,494	1,53
nvested capital	6,967	7,529	7,669	7,731	7,78
Includes convertibles and preferred stock which is be	ing treated as debt				
Per share (THB)					
Book value per share	0.68	0.68	0.72	0.78	0.8
Tangible book value per share	0.68	0.67	0.71	0.77	0.84
Financial strength					
Net debt/equity (%)	(14.4)	(8.2)	(11.3)	(17.1)	(22.5
Net debt/total assets (%)	(11.0)	(6.3)	(9.3)	(14.2)	(18.7
Current ratio (x)	3.0	2.9	2.6	2.9	3.:
CF interest cover (x)	198.7	29.9	31.6	(585.6)	(300.4
Valuation	2022	2023	2024E	2025E	2026
Recurring P/E (x) *	10.2 14.3	27.1 37.9	23.6 32.9	20.4 28.5	18.0 25.9
Recurring P/E @ target price (x) *	14.3 10.2	37.9 27.1			2 <b>5.</b> 3
Reported P/E (x)		27.1 2.7	23.6	20.4	
Dividend yield (%) Price/book (x)	6.2 3.8	3.8	2.5 3.6	2.9 3.3	3. 3.
	3.8	3.8	3.6	3.3	3. 3.
Price/tangible book (x)					
EV/EBITDA (x) ** EV/EBITDA @ target price (x) **	7.0 9.8	15.4 21.6	13.5 18.9	11.8 16.6	10. 15
- ALFOLLOW (M raider hince (x)	9.0				15.
EV/invested capital (x)	4.0	3.7	3.6	3.5	3.

Sources: Chularat Hospital; FSSIA estimates

# **Chularat Hospital PCL (CHG TB)**



## **Exhibit 2: FSSIA ESG score implication**

38.25 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
****	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

## Exhibit 3: ESG – peer comparison

	FSSIA		Domestic ratings					Global ratings					Bloomberg		
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Υ	Υ	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
ВН	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Υ	Y	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

Sources: SETTRADE.com; FSSIA's compilation

## Exhibit 4: ESG score by Bloomberg

FY ending Dec 31	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	_	_	2.21	2.34
BESG environmental pillar score	_	_	4.04	4.18
BESG social pillar score	_	_	0.74	0.79
BESG governance pillar score	_	_	4.19	4.49
ESG disclosure score	36.82	36.82	41.54	50.24
Environmental disclosure score	16.49	16.49	17.67	32.92
Social disclosure score	12.70	12.70	19.41	30.29
Governance disclosure score	81.10	81.10	87.36	87.36
Environmental				
Emissions reduction initiatives	Yes	Yes	Yes	Yes
Climate change policy	No	No	Yes	Yes
Climate change opportunities discussed	No	No	No	No
Risks of climate change discussed	No	No	No	No
GHG scope 1	0	0	0	0
GHG scope 2 location-based	4	4	4	4
GHG Scope 3	1	1	1	1
Carbon per unit of production	_	_	_	_
Biodiversity policy	No	No	No	No
Energy efficiency policy	Yes	Yes	Yes	Yes
Total energy consumption	_	_	_	_
Renewable energy use	_	_	_	_
Electricity used	4	4	4	7
Fuel used - natural gas	_	_	_	_

 $Sources: Bloomberg; FSSIA's \ compilation$ 

**Exhibit 5: ESG score by Bloomberg** (cont.)

FY ending Dec 31	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No	No
Waste reduction policy	Yes	Yes	Yes	Yes
Hazardous waste	0	0	0	(
Total waste	1	1	1	•
Waste recycled	0	0	0	(
Waste sent to landfills	_	_	_	_
Environmental supply chain management	No	No	No	No
Water policy	No	No	Yes	Yes
Water consumption	89	73	80	70
Social				
Human rights policy	Yes	Yes	Yes	Ye
Policy against child labor	Yes	Yes	Yes	Ye
Quality assurance and recall policy	No	No	No	N
Consumer data protection policy	Yes	Yes	Yes	Ye
Equal opportunity policy	Yes	Yes	Yes	Ye
Gender pay gap breakout	No	No	No	N
Pct women in workforce	_	_	84	8
Pct disabled in workforce	_	_	_	-
Business ethics policy	Yes	Yes	Yes	Ye
Anti-bribery ethics policy	Yes	Yes	Yes	Ye
Health and safety policy	Yes	Yes	Yes	Ye
Lost time incident rate - employees	_	_	_	
Total recordable incident rate - employees	_	_	_	_
Training policy	Yes	Yes	Yes	Ye
Fair remuneration policy	No	No	No	N
Number of employees – CSR	3,612	3,616	3,871	4,52
Employee turnover pct		-	20	2
Total hours spent by firm - employee training	_	_	32,904	85,88
Social supply chain management	No	No	No	00,00 N
Governance				
Board size	12	12	12	1
No. of independent directors (ID)	4	4	4	-
No. of women on board	2	2	2	
No. of non-executive directors on board	11	11	11	1
Company conducts board evaluations	Yes	Yes	Yes	Ye
No. of board meetings for the year	6	7	7	10
Board meeting attendance pct	100	100	95	10
	3	3	3	10
Board duration (years)	No	No	No	N
Director share ownership guidelines				
Age of the youngest director	60	62	63	5
Age of the oldest director	77	78	79	8
No. of executives / company managers	6	6	6	
No. of female executives	2	2	2	
Executive share ownership guidelines	No	No	No	N
Size of audit committee	3	3	3	
No. of ID on audit committee	3	3	3	
Audit committee meetings	5	5	5	
Audit meeting attendance %	100	100	100	10
Size of compensation committee	5	5	5	
No. of ID on compensation committee	4	4	4	
No. of compensation committee meetings	2	2	2	
Compensation meeting attendance %	100	100	83	10
Size of nomination committee	5	5	5	
No. of nomination committee meetings	2	2	2	
Nomination meeting attendance %	100	100	83	10
Sustainability governance				
Verification type	No	No	No	N

Sources: Bloomberg; FSSIA's compilation

## **Disclaimer for ESG scoring**

ESG score	Mathadalaa	. J			Pating					
ESG score	Methodolog		transparent miles he	component salastias	Rating	and invited to t	ho appual COD (	Clobal Carra	ato	
The Dow Jones Sustainability	process base from the ann	ed on the com	transparent, rules-based npanies' Total Sustainabili pal Corporate Sustainabili	ity Scores resulting ty Assessment (CSA).	Be a member and invited to the annual S&P Global Corporate Sustainability Assessment (CSA) for DJSI. Companies with an S&P Global ESG Score of less than 45% of the S&P Global ESG Score of the highest serving company are diagnalified. The constituents of the DJSI indices are					
ndices ( <u>DJSI</u> ) By S&P Global	inclusion.	-ranked comp	anies within each industr	y are selected for	scoring company are disqualified. The constituents of the DJSI indices are selected from the Eligible Universe.					
Sustainability nvestment		•	ility in Environmental and	•	To be eligible for <u>THSI inclusion</u> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI					
ist ( <u>THSI</u> )			preemptive criteria, with	•	during the asse	ssment year.	The scoring will I	be fairly weigh		
y The Stock Exchange of			ne board members and ex				y and materiality.		aa 1\ maarkat	
hailand			s, and combined holding nualifying criteria include:				from the THSI co D150b); 2) free fl			
(SET)	70%; 2) inde wrongdoing	pendent directive pendent dire	ctors and free float violation, social & environmental integratings in red for > 3 years	n; 3) executives' mpacts; 4) equity in	>0.5% of paid-	up capital for a et capitalisation	at least 9 out of 1 on-weighted inde	2 months. The	e SETTHSI	
CG Score	An indicator	of CG strengt	th in sustainable developn	nent, measured	Scores are rate	d in six categ	ories: 5 for Excel			
by Thai Institute of			with support from the Sto ts are from the perspective				)-79), 2 for Fair (6 w 50. Weightings			
Directors	an evaluatio	n of operation	S.				nolders (weight 2			
Association (Thai IOD)					responsibilities		sure & transpare	ency (15%); ar	nd 5) board	
AGM level			which shareholders' rights				four categories:		` ''	
By Thai Investors			d into business operations y disclosed. All form impo		Very Good (90-	.99), 3 for Fair	(80-89), and not	rated for sco	res below 79.	
Association			ents to be evaluated ann							
(TIA) with support from			lures before the meeting (	· /·						
the SEC	circulation of s	ufficient informa	meeting (10%). (The first a tion for voting; and 2) facilitati	ing how voting rights can be						
			ses 1) the ease of attending mess for Q&A. The third involve							
Thai CAC			les, resolutions and voting res Checklist include corruption		The decument	will be review	ad by a committe	o of nino prof	ossionals A	
By Thai			rols, and the monitoring a	,	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council					
Private Sector	•		is good for three years.				re twelve highly i	respected indi	viduals in	
Collective Action Against			ne a CAC certified member st f an 18-month deadline to sub		professionalism	n and ethical a	ichievements.			
Corruption	Certification, in	ncluding risk ass	sessment, in place of policy ar	nd control, training of						
(CAC)			tablishment of whistleblowing Il stakeholders.)	cnanneis, and						
Morningstar Sustainalytics			isk rating provides an ove of how much of a compar				score is the sum		ed risk. The	
<u>Sustamarytics</u>	risk is unmar	naged. Source:	s to be reviewed include corp her media, NGO reports/webs	orate publications and	more risk is uni	nanayeu, me	Tilgilei Loo lisk	is scoreu.		
	information, co		k, ESG controversies, issuer		NEGL Low Medium High Severe					
					0-10	10-20	20-30	30-40	40+	
ESG Book	positioned to the principle helps explair over-weighting	outperform o of financial m n future risk-a	sustainable companies the over the long term. The m- ateriality including inform djusted performance. Mat ith higher materiality and erly basis.	ethodology considers ation that significantly teriality is applied by	scores using m	ateriality-base	ated as a weight d weights. The s ndicating better p	core is scaled		
MSCI .			measure a company's mand laggards according to						nethodology to	
	AAA	8.571-10.00	Leader:	leading its industry in m	nanaging the most s	gnificant ESG ri	sks and opportunitie	es		
	AA	7.143-8.570	0	J,	5 5		11			
	Α	5.714-7.142		a mixed or unexception	al track record of	anaging the mas	et eignificent ESC ==	eke and opported	nities relative to	
	BBB	4.286-5.713	-	industry peers	ai ii aun Teuulu ol M	anaying life 1110s	n aigiiiii0aiii E30 fis	ana anu opportu	muco relative (0	
	ВВ	2.857-4.285								
	В	1.429-2.856	Laggard:	lagging its industry base	ed on its high expos	ure and failure t	o manage significar	nt ESG risks		
4 11 500	CCC	0.000-1.428	8						p	
Moody's ESG solutions	believes that	t a company ir	gree to which companies ntegrating ESG factors int or shareholders over the i	to its business model and						
Refinitiv ESG rating	based on pu	blicly available	and objectively measure e and auditable data. The ita publicly. (Score ratings a	score ranges from 0 to	100 on relative E	SG performar	nce and insufficie	nt degree of t		
			ore is a relative score meanin the same industry clas				of ESG risks, op	portunities, ar	id impacts	
S&P Global	compared to									
S&P Global  Bloomberg	ESG Score	<u> </u>	score is based on Bloor	ating the company's agg nberg's view of ESG fina the weights are determin	ancial materiality.	The score is	a weighted gener	ralized mean	(power mean)	

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

#### **GENERAL DISCLAIMER**

## ANALYST(S) CERTIFICATION


#### Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

### History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
27-Oct-2021	BUY	4.70	03-Aug-2023	BUY	3.90	30-Jan-2024	BUY	3.90
09-Feb-2023	BUY	4.40	03-Nov-2023	BUY	4.00	17-Jul-2024	BUY	3.60

Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Chularat Hospital	CHG TB	THB 2.58	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.

Source: FSSIA estimates

#### **Additional Disclosures**

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 22-Aug-2024 unless otherwise stated.

### RECOMMENDATION STRUCTURE

## Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price\* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

\* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

#### **Industry Recommendations**

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

#### **Country (Strategy) Recommendations**

**Overweight (O).** Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Neutral (N).** Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Underweight (U).** Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.